PubMed Health⌕ Search

PubMed · 11424895

Guidelines for devices and choices.

Abstract

Asthma patients can be treated safely and effectively with the compounds and inhalation devices currently available. However, the choice of devices is so wide that the healthcare professional may be easily confused, and the effectiveness of treatment reduced. Clear guidelines are needed to help resolve this difficulty; however, those currently available do not contain enough useful information on the different delivery systems to assist the selection process. The function of the anti-asthma drug (i.e., preventer or reliever) should determine the choice of device. For inhaled corticosteroids, the device should provide effective and reliable delivery, while simplicity in use will aid good inhalation technique. A device that minimizes systemic absorption of these drugs will improve drug safety. The devices of choice are pressurized metered dose-inhalers (pMDIs) with spacers and some dry powder inhalers (DPIs). The main selection criteria for short-acting beta2-agonists are portability and patient acceptability. DPIs and pMDIs are the most suitable systems for these drugs. Cost is an important consideration for both drug types.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M L Everard. 2001. Guidelines for devices and choices.. https://doi.org/10.1089/08942680150506358

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗